CARM - יחס חוב להיוון בספרים carismatx.com

The correlation between financial liabilities and the book capitalization of Carisma Therapeutics (CARM) demonstrates the impact of the CAR-M platform's clinical successes and partnership payments on the capital structure. The 0.00 mark characterizes this parameter, considering the role of CT-0508 and the collaboration with Moderna. Despite support from the pharma behemoth, a narrow development focus creates portfolio concentration risks, which directly affects the company's debt sustainability.

Defensive assets are selected based on the criterion of minimal debt load. Carisma Therapeutics (CARM) faces financial instability due to the high cost of developing macrophage therapy and the risks associated with insurance payments. The metric compares total liabilities to equity on the balance sheet. By analyzing the value of borrowed capital relative to book capitalization, an investor assesses the risk of debt servicing. An increase in this indicator signals a potential value trap.